Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Hall

Showing results (151-160 of 225) with videos related to

Pageof 23
Sort By:
Clinical and Translational Radiation Oncology|March 5, 2024
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM studyKobika Sritharan, Lois Daamen, Angela Pathmanathan, et al.
British Journal of Cancer|April 13, 2016
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicityMahbubl Ahmed, Leila Dorling, Sarah Kerns, et al.
Frontiers in Oncology|August 15, 2020
Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III TrialsMarco Marcello, James W Denham, Angel Kennedy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 4, 2020
Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trialsMarco Marcello, James W Denham, Angel Kennedy, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2020
Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 TrialsMarco Marcello, James W Denham, Angel Kennedy, et al.
BJU International|March 4, 2020
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancerA Hugh Mostafid, Nuria Porta, Joanne Cresswell, et al.
Radiology|October 2, 2019
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response MarkerJessica M Winfield, Jennifer C Wakefield, David Dolling, et al.
Biomolecules|April 30, 2025
Effects of Testosterone and Its Major Metabolites upon Different Stages of Neuron Survival in the Dentate Gyrus of Male RatsMark D Spritzer, Ethan A Roy, Kelsey M K Calhoun, et al.
European Urology|March 4, 2018
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, David Dolling, Semini Sumanasuriya, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
Pageof 23

Showing results (151-160 of 225) with videos related to

Sort By:
Pageof 23
Clinical and Translational Radiation Oncology|March 5, 2024
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM studyKobika Sritharan, Lois Daamen, Angela Pathmanathan, et al.
British Journal of Cancer|April 13, 2016
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicityMahbubl Ahmed, Leila Dorling, Sarah Kerns, et al.
Frontiers in Oncology|August 15, 2020
Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III TrialsMarco Marcello, James W Denham, Angel Kennedy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 4, 2020
Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trialsMarco Marcello, James W Denham, Angel Kennedy, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2020
Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 TrialsMarco Marcello, James W Denham, Angel Kennedy, et al.
BJU International|March 4, 2020
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancerA Hugh Mostafid, Nuria Porta, Joanne Cresswell, et al.
Radiology|October 2, 2019
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response MarkerJessica M Winfield, Jennifer C Wakefield, David Dolling, et al.
Biomolecules|April 30, 2025
Effects of Testosterone and Its Major Metabolites upon Different Stages of Neuron Survival in the Dentate Gyrus of Male RatsMark D Spritzer, Ethan A Roy, Kelsey M K Calhoun, et al.
European Urology|March 4, 2018
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, David Dolling, Semini Sumanasuriya, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
Pageof 23